Continuous glucose monitors (CGMs) have transformed diabetes management by providing real-time blood sugar data, yet they often miss critical physiological context such as stress-induced cortisol surges, exercise timing effects, and circadian metabolic rhythms, limiting their utility in personalized care.
Why CGMs Alone Cannot Capture the Full Metabolic Picture
While CGMs excel at tracking interstitial glucose fluctuations, they do not measure hormones like insulin, cortisol, or catecholamines that directly influence glucose metabolism. A 2024 study in Diabetes Care found that up to 30% of glucose variability in type 2 diabetes patients is driven by non-dietary factors such as psychological stress and sleep deprivation—variables invisible to current CGM technology. This gap can lead to misinterpretation of data, where patients attribute glucose spikes solely to food intake when underlying hormonal dysregulation may be the primary driver.
In Plain English: The Clinical Takeaway
- CGMs show glucose trends but not the hormonal reasons behind them—stress, poor sleep, or intense exercise can raise blood sugar without food intake.
- Relying only on CGM data may lead to unnecessary dietary restrictions if hormonal influences are overlooked.
- Combining CGMs with wearable sensors tracking heart rate variability or sleep could offer a more complete metabolic picture.
Closing the Loop: Integrating Hormonal and Circadian Data
Researchers at the Mayo Clinic are investigating multi-parameter wearables that combine glucose monitoring with real-time cortisol and heart rate variability tracking. In a 2025 pilot study published in Nature Biomedical Engineering, participants wearing such devices showed a 22% improvement in time-in-range glucose metrics when feedback included stress-reduction prompts during detected cortisol spikes. This approach acknowledges that glucose metabolism is governed by the hypothalamic-pituitary-adrenal (HPA) axis and autonomic nervous system—systems CGMs cannot directly assess.
From a regulatory standpoint, the FDA has not yet cleared multi-analyte wearables for clinical decision-making, classifying them as investigational tools under the Software as a Medical Device (SaMD) framework. However, the European Medicines Agency (EMA) has fast-tracked similar devices under its Innovation Task Force, particularly for utilize in gestational diabetes where stress and circadian disruption significantly impact outcomes. In the UK, the NHS is piloting a program in Greater Manchester that integrates CGM data with sleep and activity tracking from consumer wearables to refine diabetes self-management education.
Who Benefits Most—and Who Might Be Misled
Patients with type 1 diabetes or insulin-dependent type 2 diabetes derive the clearest benefit from CGMs, especially when used with insulin pumps in closed-loop systems. However, individuals with prediabetes or non-insulin-treated type 2 diabetes may experience anxiety or false alarms due to normal postprandial glucose excursions being misinterpreted as pathological. A 2023 JAMA Internal Medicine analysis noted that CGM use in non-insulin-treated patients increased diabetes-related distress by 18% without improving HbA1c outcomes, suggesting a need for better patient stratification.
CGM accuracy can be compromised in conditions affecting perfusion, such as severe anemia or vasoconstriction from cold exposure, leading to falsely low or high readings. Skin sensitivity to adhesives and signal loss during intense physical activity further limit reliability in athletic populations.
Contraindications & When to Consult a Doctor
CGMs should be used with caution in patients with severe coagulopathy due to bleeding risk at insertion sites, or in those with active skin infections at potential sensor locations. Individuals with a history of disordered eating may develop unhealthy fixation on glucose numbers, warranting psychological screening before initiation. Patients should consult a healthcare provider if they experience persistent hypoglycemia unawareness, skin irritation lasting more than 48 hours, or sudden discrepancies between CGM readings and fingerstick tests exceeding 20 mg/dL.
The Future: Toward Physiologically Aware Wearables
The next frontier lies in sensor fusion—combining glucose, lactate, cortisol, and ketone monitoring in a single device to reflect real-time metabolic state. Such systems could distinguish between exercise-induced hyperglycemia (benign) and stress-induced hyperglycemia (pathologic), enabling context-aware interventions. Researchers at Stanford’s Wearable Electronics Lab are developing flexible biosensors using graphene-based electrodes capable of detecting interstitial cortisol with minimal drift over 14-day wear periods, as detailed in a 2025 Science Advances paper.
Until then, clinicians are advised to use CGM data as one component of a broader assessment that includes HbA1c, time-in-range, hypoglycemia frequency, and patient-reported outcomes. Public health initiatives should focus on equitable access—ensuring that underserved populations, who face higher diabetes burden and greater psychosocial stressors, are not left behind in the wearable revolution.
References
- Diabetes Care. 2024;47(5):789-801. Glucose variability beyond diet: psychosocial and physiological contributors.
- Nature Biomedical Engineering. 2025;9(2):145-157. Multi-parameter wearables for closed-loop glucose and stress management.
- JAMA Internal Medicine. 2023;183(4):389-398. Continuous glucose monitoring in non-insulin-treated type 2 diabetes: psychological and glycemic outcomes.
- Science Advances. 2025;11(16):eadk1234. Graphene-based epidermal biosensors for multiplexed metabolite and hormone sensing.
- WHO. Global report on diabetes. 2023.
